Latest Articles
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial - Yahoo Finance
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial Yahoo Finance
Published: July 27, 2026, 10:08 p.m.
Dublin woman Catriona Doyle was diagnosed with endometrial cancer during surgery for ovarian cancer - RSVP Live
Dublin woman Catriona Doyle was diagnosed with endometrial cancer during surgery for ovarian cancer RSVP Live
Published: July 24, 2026, 6:04 p.m.
Premenopausal and postmenopausal obesity and endometrial cancer risk: circulating biomarkers of inflammation, insulin resistance, and sex hormones as mediators - Escuela Andaluza de Salud Pública
Premenopausal and postmenopausal obesity and endometrial cancer risk: circulating biomarkers of inflammation, insulin resistance, and sex hormones as mediators Escuela Andaluza de Salud Pública
Published: July 22, 2026, 9:19 a.m.
Merck's Keytruda Meets Primary Endpoint in Phase 3 Frontline Endometrial Cancer Trial - BioPharm International
Merck's Keytruda Meets Primary Endpoint in Phase 3 Frontline Endometrial Cancer Trial BioPharm International
Published: July 16, 2026, 9:06 p.m.
Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer - Oncodaily
Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer Oncodaily
Published: July 16, 2026, 4:40 p.m.
Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer - CancerNetwork
Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer CancerNetwork
Published: July 16, 2026, 3:40 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Sahm
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Sahm
Published: July 16, 2026, 10:27 a.m.
Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper - Seoul Economic Daily
Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper Seoul Economic Daily
Published: July 16, 2026, 5:33 a.m.
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk
Published: July 15, 2026, 11:49 p.m.
Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first - Fierce Pharma
Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first Fierce Pharma
Published: July 15, 2026, 7:33 p.m.
Link copied to clipboard!